DriveWealth Names Naureen Hassan Chief Executive Officer
20.8.2025 17:00:00 EEST | Business Wire | Press release
DriveWealth, a leading financial technology platform providing Brokerage-as-a-Service, has announced the appointment of Naureen Hassan as Global Chief Executive Officer (CEO). Hassan succeeds Michael Blaugrund, who is stepping down as CEO to accept a newly created position at ICE (Intercontinental Exchange).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250820719951/en/
DriveWealth welcomes Naureen Hassan as its new CEO.
Hassan joins DriveWealth with decades of deep expertise in digital and product innovation, operational excellence and regulatory management across global banking and wealth management. She will guide the company’s operations, lead its continued growth and expansion across markets, and help fulfill DriveWealth’s mission of democratizing investing around the world.
“Michael has overseen a period of significant growth, expansion into new markets and profitability over the last two years as CEO and we thank him for everything that he has accomplished,” said Robert Cortright, DriveWealth Founder and Executive Chairman. “Naureen has a proven track record as an industry innovator and disruptor and is the perfect person to lead DriveWealth through our continued evolution and next phase of growth. She joins us during a period of accelerating growth, and we look forward to all that is to come under her visionary leadership.”
Prior to DriveWealth, Hassan served as President of UBS Americas, where she led a $14B revenue division with more than 25,000 employees, while also spearheading UBS’s integration of Credit Suisse in the Americas—the first-ever acquisition between two globally systemically important financial institutions. She also worked at the Federal Reserve Bank of New York, where she drove innovations across payment operations, technology, human resources, risk management, and finance.
Before joining the Fed, Hassan served as Chief Digital Officer of Morgan Stanley’s Wealth Management business and drove strategy and platform innovation for Charles Schwab’s Investor Services division. She began her career at McKinsey & Company.
“DriveWealth is truly changing how and where people invest and providing unique value and capabilities to partners across the globe,” Hassan said. “I am honored to step into this role, to continue building on the great work Robert and Michael have done, and to help guide the company’s continued growth and success. DriveWealth has grown by opening doors to new opportunities for investors in new markets and we will continue to work toward realizing the company’s potential as the market’s most trusted embedded investing technology partner.”
A leading provider of Brokerage-as-a-Service and other critical investment infrastructure, DriveWealth operates in markets across five continents, including the U.S., the EU/UK, South Korea, Australia and New Zealand, and Brazil. The company supports an average of over 2 million trades per day for its B2B partners around the world, facilitating 24-hour trading, fractional share execution and multi-asset class support for millions of individual global investors.
DriveWealth was recently named to CNBC’s “World’s Top Fintech Companies 2025” list and recognized on the 2025 Inc. 5000 list of America’s fastest-growing private companies for the second year in a row.
About DriveWealth:
DriveWealth is a global B2B financial technology platform. Our core business is providing Brokerage-as-a-Service, powering the investing and trading experiences for digital wallets, broker dealers, asset managers, and consumer brands. DriveWealth’s APIs provide our partners with a modern, extensible and flexible toolkit to develop everything from traditional investment workflows to more innovative techniques like rounding up purchases into fractional share ownership. For more information, visit www.drivewealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250820719951/en/
Contacts
Media Contact:
Ryan Hall
Caliber Corporate Advisers
drivewealth@calibercorporate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom